AGLE

Aeglea BioTherapeutics, Inc. is a biotechnology company engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its lead product candidate, pegzilarginase, is engineered to degrade the amino acid arginine and is being developed to lower arginine levels in patients with Arginase I Deficiency. Its AEB4104 product candidate is a recombinant human enzyme that degrades the amino acid homocysteine and its oxidized form homocystine. It is developing AEB4104 for the treatment of patients with cystathionine beta synthase (CBS) deficiency. Its AEB5100 products candidate is a recombinant human enzyme that degrades plasma cystine and cysteine. It is developing AEB5100 product candidate for the treatment of patients with cystinuria. Its AEB3103 product candidate is an engineered human enzyme that targets the degradation of the amino acid cysteine/cystine.